|
1.
|
Itoh K, Yamada A, Mine T and Noguchi M:
Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol.
39:73–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Itoh K and Yamada A: Personalized peptide
vaccines: a new therapeutic modality for cancer. Cancer Sci.
97:970–976. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Finn OJ: Cancer immunology. N Engl J Med.
358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Parker KC, Bednarek MA and Cokigan JE:
Scheme for ranking potential HLA-A2 binding peptides based on
independent binding of individual peptide side-chains. J Immunol.
152:163–175. 1994.PubMed/NCBI
|
|
5.
|
Rammensee HG, Friede T and Stevanoviic S:
MHC ligands and peptide motifs: first listing. Immunogenetics.
41:178–228. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Imanishi T, Akazawa T, Kimura A, Tokunaga
K and Gojobori T: Allele and haplotype frequencies for HLA and
complement loci in various ethnic groups. HLA 1991, Vol. 1. Tsuji
K, Aizawa M and Sasazuki T: Oxford Scientific Publications; Oxford:
pp. 1065–1220. 1992
|
|
7.
|
Sidney J, Grey HM, Southwood S, Celis E,
Wentworth PA, del Guercio MF, Kubo RT, Chesnut RW and Sette A:
Definition of an HLA-A3-like supermotif demonstrates the
overlapping peptide-binding repertoires of common HLA molecules.
Hum Immunol. 45:79–93. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Noguchi M, Kobayashi K, Suetsugu N,
Tomiyasu K, Suekane S, Yamada A, Itoh K and Noda S: Induction of
cellular and humoral immune responses to tumor cells and peptides
in HLA-A24 positive hormone-refractory prostate cancer patients by
peptide vaccination. Prostate. 57:80–92. 2003. View Article : Google Scholar
|
|
9.
|
Noguchi M, Itoh K, Suekane S, Yao A,
Suetsugu N, Katagiri K, Yamada A, Yamana H and Noda S: Phase I
trial of patient-oriented vaccination in HLA-A2-positive patients
with metastatic hormone-refractory prostate cancer. Cancer Sci.
95:77–84. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Noguchi M, Itoh K, Suekane S, Morinaga A,
Sukehiro A, Suetsugu N, Katagiri K, Yamada A and Noda S:
Immunological monitoring during combination of patient-oriented
peptide vaccination and estramustine phosphate in patients with
metastatic hormone refractory prostate cancer. Prostate. 60:32–45.
2004. View Article : Google Scholar
|
|
11.
|
Takedatsu H, Shichijo S, Katagiri K,
Sawamizu H, Sata M and Itoh K: Identification of peptide vaccine
candidates sharing among HLA-A3+, -A11+,
-A31+, and -A33+ cancer patients. Clin Cancer
Res. 10:1112–1120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Minami T, Matsueda S, Takedatsu H, Tanaka
M, Noguchi M, Uemura H, Itoh K and Harada M: Identification of
SART3-derived peptides having the potential to induce
cancer-reactive cytotoxic T lymphocytes from prostate cancer
patients with HLA-A3 supertype alleles. Cancer Immunol Immunother.
56:689–698. 2007. View Article : Google Scholar
|
|
13.
|
Naito M, Komohara Y, Ishihara Y, Noguchi
M, Yamashita Y, Shirakusa T, Yamada A, Itoh K and Harada M:
Identification of Lck-derived peptides applicable to anti-cancer
vaccine for patients with human leukocyte antigen-A3 supertype
alleles. Br J Cancer. 97:1648–1654. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Hida N, Maeda Y, Katagiri K, Takasu H,
Harada M and Itoh K: A simple culture protocol to detect
peptide-specific cytotoxic T lymphocyte precursors in the
circulation. Cancer Immunol Immunother. 51:219–228. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bjorkman PJ, Saper MA, Samraoui B, Bennett
WS, Strominger JL and Wiley DC: The foreign antigen binding site
and T cell recognition regions of class I histocompatibility
antigens. Nature. 329:512–518. 1987. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wheatley AP, Bolland DJ, Hewitt JE, Dewar
JC and Hall IP: Identification of the autoantigen SART-1 as a
candidate gene for the development of atopy. Hum Mol Genet.
11:2143–2146. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Terasaki Y, Shichijo S, Niu Y, Komatsu N,
Noguchi M, Todo S and Itoh K: An HLA-A3-binding prostate acid
phosphatase-derived peptide can induce CTLs restricted to HLA-A2
and -A24 alleles. Cancer Immunol Immunother. 58:1877–1885. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Mohamed ER, Naito M, Terasaki Y, Niu Y,
Gohara S, Komatsu N, Shichijo S, Itoh K and Noguchi M: Capability
of SART3(109-118) peptide to induce cytotoxic T lymphocytes from
prostate cancer patients with HLA class I-A11, -A31 and -A33
alleles. Int J Oncol. 34:529–536. 2009.PubMed/NCBI
|
